愛沙尼亞CeMines  www.cemines.com
生命科學和生物技術(shù)領(lǐng)域的新專家，專業(yè)提供分子研究工具、診斷產(chǎn)品、先進療法（如將基因功能研究應(yīng)用于癌癥療法）
CeMines was founded in 2000 by Richard Cavalli, Dr. Toomas Neuman, Ph.D. and Dr. Kaia Palm, Ph.D. to develop cancer diagnostics using two methods: auto-antibody and splice variants.

Our focus is on the early, and accurate detection of Cancer within the human body with an initial product focus on Lung Cancer.

We are creating molecular diagnostics for cancer based on a simple blood test. This method analyzes a drop of blood for the presence of antibodies your body produces to fight cancer. Our approach identifies cancer before it spreads and provides a preventative measure for “at-risk” populations.

Our R&D is focused on diagnostic tests for lung, breast, gastrointestinal and leukemia. In addition to cancer, however, our science has applications for Immune disorders such as Hepatitis C, HIV and Rheumatoid Arthritis. We are also extending our methods to transplant donor matching applications.

CeMines Corporate Headquarters is in Golden, Colorado and our Scientific Laboratories are in Tallinn, Estonia.